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Tenofovir disoproxil fumarate (TDF) is a prodrug of tenofovir (TFV), a nucleotide reverse 22 transcriptase inhibitor with potent activity against HIV-1 and hepatitis B. Although TDF has a 23 favourable safety profile, the plasma TFV concentrations obtained with TDF exposure have been 24 shown to result in a degree of renal tubular dysfunction (1, 2) . Manifestations of renal tubular 25 dysfunction include proteinuria (predominantly low molecular weight proteins) and increased 26 fractional excretion of phosphate and urate (3). Older age and genetic polymorphisms in the tubular 27 transporters ABCC2, 4 and 10 (encoding multidrug resistant proteins 2, 4 and 7 respectively) have 28 been associated with higher TFV concentrations and renal tubular dysfunction (4-9). In cohort 29 studies, TDF has also been associated with accelerated decline of estimated glomerular filtration 30 rate (eGFR) and chronic kidney disease (CKD) (10-12). Hence, guidelines suggest that renal function 31 should be monitored regularly in patients who receive TDF-containing antiretroviral therapy (ART) 32 (13) . 33
In a small proportion of patients, TDF may cause Fanconi syndrome (a well described proximal renal 34 tubulopathy, PRT) accompanied by acute tubular injury (ATI) on kidney biopsy (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) . PRT is 35 characterised by normoglycaemic glycosuria, proteinuria, renal phosphate wasting and metabolic 36 acidosis which may be accompanied by reductions in bone mineral density, osteomalacia and/or 37 fragility fractures (3, 14, 25, 26) . The risk factors for developing PRT have not been studied 38 comprehensively to date. Case reports, case series and a small case-control study have suggested 39 that older age, immunodeficiency, renal impairment and co-exposure to didanosine (ddI) or boosted 40 protease inhibitors (PI) may increase the risk of . The purpose of the present study was to 41 describe the clinical phenotype of TDF-induced treatment-limiting PRT using the largest cohort of 42 individuals collected to date, and, using data from the UK CHIC study, analyse the risk factors for 43 developing renal tubulopathy (PRT/ATI). 44
A multi-centre study was undertaken in HIV clinics which contribute data to the UK CHIC study, a 46 large multicentre observational cohort study of HIV positive adults in the UK (27). Cases of 47 treatment-limiting renal tubulopathy were identified retrospectively through searches of electronic 48 databases and physician recall. Clinical and laboratory data were collected on case report forms. The 49 study was approved by the National Health Service Research Ethics Committee. 50 All cases were reviewed by two clinicians (LH and FAP) and included in the analyses if they had 51 required TDF discontinuation and biochemical evidence of PRT or histological evidence of ATI that 52 was not explained by other aetiologies (28). PRT was defined by the presence of at least 2 of the 53 following: normoglycaemic glycosuria (>1+ on dipstick), hypophosphataemia (serum phosphate 54 <1.98 mg/dl), proteinuria (>1+ on dipstick or protein/creatinine ratio (PCR) >26.5 mg/mg), 55 hypokalaemia (serum potassium <3·0 mEq/l), and metabolic acidosis (serum bicarbonate <19 mEq/l) 56 (19) . Reductions in eGFR from baseline were not a prerequisite for inclusion in the study. 57
Comparator subjects were individuals in the UK CHIC study who had attended a centre from which 58 cases were drawn and who had been exposed to a TDF-containing ART regime without having 59 developed RT. Follow up was from the date of starting TDF to either the date of stopping TDF or the 60 last visit (up to 31st December 2013) if TDF was not discontinued. 61
Baseline variables, including CD4 cell count, HIV viral load (expressed as log 10 ), eGFR (calculated by 62 CKD-Epi (29)), hepatitis B (HBV surface antigen) and hepatitis C (HCV antibody) status, were defined 63 as the most recent measurement prior to starting TDF and compared using Chi squared, Fisher's 64 exact or Wilcoxon rank sum tests, depending on the variable distribution. Poisson regression analysis 65 was used to investigate factors associated with renal tubulopathy(30). Age, sex, ethnicity (black vs. 66 white/other), AIDS, eGFR at start TDF and year of starting TDF were included as fixed covariates, and 67 hepatitis B and C status, nadir and current CD4 cell count (per 50 cells/mm 3 increase), HIV RNA (per 68 M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 4 multivariable models in a forward stepwise approach. We performed a sensitivity analysis restricted 71 to individuals with PRT. 72
We analysed eGFR slopes on TDF in the renal tubulopathy cases and the comparators who had ≥3 73 eGFR values while receiving TDF using mixed effects models in which time was considered as a 74 continuous fixed effect (allowing a random intercept for time) and as a random effect (allowing the 75 slope to vary) (31). Adjusted eGFR slopes were determined using multivariate models; covariates 76 considered for inclusion included demographic and HIV characteristics, including fixed covariates 77 such as ethnicity and time updated covariates such as age, PI use, CD4 cell count and viral load. In 78 additional analyses, the last six months of eGFR results on TDF were excluded to determine if the 79 mean slope was unduly influenced by eGFR reductions just prior to stopping TDF. Assumptions for 80 multivariate models were tested graphically. We compared the proportions of subjects with and 81 without renal tubulopathy who experience rapid eGFR decline (defined as a mean decline in eGFR >3 82 or >5 ml/min/1·73m 2 /year) or incident CKD while receiving TDF using Chi squared tests. All analyses 83 were performed using STATA version 12 (StataCorp LP, College Station, Tx). 84
Results 85

Baseline characteristics 86
Between October 2002 and June 2013, 15983 patients received at least four weeks of TDF-87 containing antiretroviral therapy (ART). During a median follow up of 4·1 (IQR 1·8, 6·7) years, 88 treatment-limiting renal tubulopathy was diagnosed in 69 (0·4%) subjects, of whom 60 (87%) were 89 included in the present analyses; 48 met the case definition of PRT and 12 had ATI on renal biopsy 90 (including four with sufficient data to confirm the presence of PRT). Nine subjects were excluded as 91 they had <2 markers of PRT and no histological evidence of ATI. 92
Factors associated with renal tubulopathy 93 M A N U S C R I P T
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Renal tubulopathy was diagnosed after a median of 44·1 (IQR 20·4, 64·4 months; range 3·9 months 94 to 11·0 years) months of TDF exposure. The subjects who were diagnosed with renal tubulopathy 95 were older at TDF initiation and more likely to be male, of white ethnicity, and to have initiated TDF 96 in earlier years than those who did not develop renal tubulopathy. The renal tubulopathy cases also 97 had lower nadir CD4 cell counts, more often a prior AIDS diagnosis, and greater prior ART exposure 98 at TDF initiation, and they were more likely to have initiated TDF with ddI or a PI. By contrast, 99 patients with and without renal tubulopathy did not differ by HBV or HCV status, current CD4 cell 100 count or eGFR at baseline (Table 1) . At renal tubulopathy diagnosis, the majority (n=54, 90%) of 101 patients received an ART regimen that contained a PI [lopinavir (LPV) in 37%, atazanavir (ATV) in 102 39%, darunavir (DRV) in 13%, other PI in 11% of subjects], and 18 (30%) subjects received ddI (15 as 103 part of a PI-containing regimen). Normoglycaemic glycosuria was present in 37/46 (80%), 104 hypophosphataemia in 41/55 (75%), proteinuria in all 55 (100%), hypokalaemia in 3/44 (7%) and 105 metabolic acidosis in 7/22 (32%) subjects with data. Nine subjects had diabetes mellitus; all diabetics 106 with glycosuria had a paired plasma glucose measurement within the normal range. In addition, 107 33/59 patients (56%) had raised serum alkaline phosphatase concentrations (with normal hepatic 108 transaminases) suggestive of osteomalacia. The median eGFR at renal tubulopathy diagnosis was 109 52·7 (IQR 44·5, 71·5) mL/min/1·73m 2 , an eGFR reduction of >25% from baseline was observed in 110 34/57 (60%) of subjects. The clinical characteristics of the PRT and ATI cases were indistinguishable 111 (Table 2) . 112
In univariate regression analysis, age, gender, ethnicity, CD4 cell count, having initiated TDF in earlier 113 calendar years and with a more prolonged ART history, and receipt of ddI and PI were associated 114 with renal tubulopathy (Table 3 ). Due to interaction between ddI and PI use (p<0·001), ART was 115 categorised in the model as no ddI/no PI, ddI/no PI, no ddI/PI or ddI/PI. In multivariate analysis, age, 116 ethnicity, calendar year, CD4 cell count, and ddI and PI use remained significantly associated with 117 renal tubulopathy (Table 2) . Similar results were obtained when the analysis was restricted to the 52 118 PRT cases (data not shown). The incidence rates of renal tubulopathy on LPV, ATV and DRV were [0·20, 2·33] mL/min/1·73m 2 /year thereafter). Adverse eGFR patterns were more common among 133 those who developed renal tubulopathy than those who did not develop renal tubulopathy: rapid 134 eGFR decline >3 mL/min/1·73m 2 /year was noted in 69·6% and 7·9% (p<0·0001), rapid eGFR decline 135 >5 mL/min/1·73m 2 /year in 55·4% and 3·5% (p<0·001), and incident CKD (eGFR <60 mL/min/1·73m 2 136 for >3 months) in 43·5% and 9·5% (p<0·0001) of patients respectively. 137
Discussion 138
This study describes the largest cohort of TDF-associated renal tubulopathy cases to date. Consistent 139 with previous case series, the majority of patients who developed renal tubulopathy were older, 140 white men. Renal tubulopathy was associated with TDF use in earlier calendar years when TDF was 141 more commonly used in PI-containing salvage ART regimens in a setting of limited appreciation of 142 the potential for renal toxicity and little if any monitoring for renal complications. Many of these 143 early patients had a history of severe immunodeficiency and prolonged ART exposure; TDF was not M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 7 infrequently co-administered with ddI, and the most commonly used PI in this era was lopinavir, 145 giving the impression that perhaps this PI predisposed patients to developing renal tubulopathy (19) . 146
The introduction of routine renal monitoring advocated by HIV management guidelines may have 147 contributed to the decline in the incidence of renal tubulopathy as patients with reduced eGFR were 148 identified earlier and switched to alternative ART (32). Interestingly, the propensity for TDF to cause 149 renal tubulopathy appears undiminished as several cases were reported in recent clinical trials in 150 which patients (with relatively high CD4 cell counts and preserved eGFR) received TDF together with 151 emtricitabine plus cobicistat/elvitegravir or ritonavir/atazanavir (33, 34) . 152
The pathogenesis of TDF-induced renal tubulopathy remains poorly understood. Proximal tubular 153 cells are highly metabolically active and renal histology of patients with tubulopathy has revealed 154 structural abnormalities of mitochondria (14-16). Relatively high CD4 cell counts argue against 155 opportunistic infection, and given that most cases had an undetectable HIV viral load, a direct action 156 of HIV appears unlikely. Boosting agents such as ritonavir and cobicistat increase systemic TFV 157 exposure by approximately 30% (35, 36) . Increased TFV exposure and PI co-administration have 158 been associated with greater eGFR decline (37-39). Organic anion transporters on the basolateral 159 membrane of proximal tubular cells allow efficient uptake of TFV while ritonavir or cobicistat are 160 potent inhibitors of apical membrane transporters involved in the extrusion of TFV from these cells; 161 high intracellular TFV concentration may affect mitochondrial function and thereby the absorptive 162 capacity of renal tubular cells (40). Of note, particularly high intracellular TFV concentrations have 163 been reported in a patient with renal tubulopathy (41). 164
Consistent with previously reported cases (21-24), we observed a strong association between renal 165 tubulopathy and TDF/ddI co-administration. Exposure to ddI (without TDF or PI) appears to be 166 sufficient to induce renal tubulopathy (42) (43) (44) (45) . Didanosine has been shown in vitro to be more toxic 167
to renal tubular cells than TFV, causing profound depletion of mitochondrial DNA and cytochrome 168 oxidase II mRNA (46). These effects of ddI were enhanced in the presence of tenofovir, which may M A N U S C R I P T
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8 be the result of TFV-mediated inhibition of purine nucleoside phosphorylase, the enzyme 170 responsible for ddI phosphorylation and degradation (21, 47) . 171
The majority of our patients who developed renal tubulopathy had received TDF for several years. 172
Interestingly, the mean eGFR slope during TDF exposure was significantly worse in cases as 173 compared to comparators, suggesting that sub-clinical renal tubular toxicity had been present 174 throughout this time. This potentially affords opportunities for early diagnosis. The role of renal 175 tubular biomarkers has been advocated but their clinical utility remains unclear (48). By contrast, 176 plasma creatinine and urinalysis for proteinuria and glycosuria are routinely available. Our data 177 suggest that patients who develop rapid eGFR decline or incident CKD while receiving TDF may be 178 particularly at risk of developing renal tubulopathy. Such patients should be switched off TDF, or 179 closely monitored if TDF is continued. The biomarker profile of tenofovir alafenamide (TAF) suggests 180 that this may be a safer option for such patients (49, 50) . 181
The strong ethnic association observed in this study is consistent with population-specific genetic 182 susceptibility factors for renal tubulopathy as described for sub-clinical renal tubular dysfunction (4-183 9). TDF is increasingly used in sub-Saharan Africa where the population is at risk of HIV-associated 184 nephropathy (HIVAN) (51) and regular monitoring of renal function may not be possible. Our 185 observation that black patients were at approximately 80% lower risk of developing renal 186 tubulopathy suggests that severe renal toxicity may be less frequent in this setting, especially if TDF 187 is used in a relatively young population as part of first line ART that does not include a PI. Of note, no 188 individuals of black ethnicity in our cohort who received TDF without a PI were diagnosed with 189 severe tubulopathy. 190
Strengths and limitations 191
The strengths of this study include the relatively large number of cases, the robust case definition, 192 and the large (and for the UK representative) population used to study the risk factors for renal 193 tubulopathy. However, some limitations need to be acknowledged. Case ascertainment was M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 9 retrospective, which is likely to have resulted in under-ascertainment. The UK CHIC study has limited 195 information on the reasons for ART discontinuation; some subjects may have been misclassified as 196 comparators where in fact they discontinued TDF for renal tubulopathy. In addition, there was no 197 information in the comparator subjects on acute clinical events, concomitant medications such as 198 nephrotoxic drugs or creatine supplements and other risk factors for renal disease such as 199 hypertension and diabetes. We were unable to include these in our model and this may have 200 introduced unmeasured confounding. Our study was also affected by incomplete data which 201 precluded assessment of the full PRT phenotype in each subject, and nine cases had to be excluded 202 for insufficient data. 203
Conclusions 204
Our study indicates that older age, white ethnicity, immunodeficiency, and co-administration of TDF 205 with ddI and PI are important risk factors for renal tubulopathy in HIV positive patients. Although 206 severe renal tubulopathy may manifest within weeks of TDF exposure, the median time to overt 207 renal toxicity in our patients was more than 3.5 years. Sub-clinical renal tubular dysfunction, as 208 manifested by rapid eGFR decline or incident CKD, preceded renal tubulopathy in the majority of 209 patients. Patients who develop these adverse eGFR patterns while receiving TDF should be 210 considered for alternative therapy or carefully monitored if they are maintained on TDF. With the 211 availability of tenofovir alafenamide (50, 52), a pro-drug with 90% reduced plasma tenofovir 212 exposure, the incidence of severe renal tubulopathy is likely to decline. A clinical trial (EudraCT 2016-213 003345-29) is currently evaluating whether patients with a history of severe renal tubulopathy on 214 TDF can be safely managed with tenofovir alafenamide (53). 215 
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